PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING WITH DECITABINE IN OLDER PATIENTS WITH AML

被引：0
|
作者：
Kadia, T. [1 ]
Cortes, J. [1 ]
Borthakur, G. [1 ]
Jabbour, E. [1 ]
Daver, N. [1 ]
Pemmaraju, N. [1 ]
Verstovsek, S. [1 ]
Burger, J. [1 ]
Ferrajoli, A. [1 ]
Wierda, W. [1 ]
Konopleva, M. [1 ]
DiNardo, C. [1 ]
Jain, N. [1 ]
Brandt, M. [1 ]
Tuttle, C. [1 ]
Wang, X. [1 ]
Ravandi, F. [1 ]
Garcia-Manero, G. [1 ]
Kantarjian, H. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P187
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [31] Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report
    Fan, Hui
    Lu, Xuechun
    Wang, Xiaohui
    Liu, Yang
    Guo, Bo
    Zhang, Yan
    Zhang, Wenying
    Nie, Jing
    Feng, Kaichao
    Chen, Meixia
    Zhang, Yajing
    Wang, Yao
    Shi, Fengxia
    Fu, Xiaobing
    Zhu, Hongli
    Han, Weidong
    JOURNAL OF IMMUNOLOGY RESEARCH, 2014, 2014
  • [32] Hemoglobin F synthesis in AML and MDS:: In vivo changes with low-dose decitabine therapy
    Claus, R.
    Hackanson, B.
    Rueter, B.
    Bisse, E.
    Luebbert, M.
    ANNALS OF HEMATOLOGY, 2006, 85 : 21 - 22
  • [33] A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML
    Welch, John S.
    Niu, Haixia
    Uy, Geoffrey L.
    Westervelt, Peter
    Abboud, Camille N.
    Vij, Ravi
    Stockerl-Goldstein, Keith E.
    Jacoby, Meagan
    Pusic, Iskra
    Schroeder, Mark A.
    Dipersio, John F.
    Cashen, Amanda F.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (08) : E103 - E108
  • [34] TREATMENT WITH LOW-DOSE CYTARABINE (LD-ARAC) IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA (AML): A SINGLE INSTITUTION EXPERIENCE
    Heiblig, M.
    El Ahmri, M.
    Tigaud, I.
    Plesa, A.
    Barraco, F.
    Labussiere-Wallet, H.
    Ducastelle-Lepretre, S.
    Michallet, M.
    Nicolini, F. E.
    Plesa, C.
    Wafter, E.
    Salles, G.
    Thomas, X.
    HAEMATOLOGICA, 2015, 100 : 382 - 382
  • [35] Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
    Jabbour, Elias
    Short, Nicholas J.
    Montalban-Bravo, Guillermo
    Huang, Xuelin
    Bueso-Ramos, Carlos
    Qiao, Wei
    Yang, Hui
    Zhao, Chong
    Kadia, Tapan
    Borthakur, Gautam
    Pemmaraju, Naveen
    Sasaki, Koji
    Estrov, Zeev
    Cortes, Jorge
    Ravandi, Farhad
    Alvarado, Yesid
    Komrokji, Rami
    Sekeres, Mikkael A.
    Steensma, David P.
    DeZern, Amy
    Roboz, Gail
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2017, 130 (13) : 1514 - 1522
  • [36] Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group
    Becker, Heiko
    Suciu, Stefan
    Rueter, Bjorn
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Labar, Boris
    Germing, Ulrich
    Salih, Helmut R.
    Muus, Petra
    Pfluger, Karl-Heinz
    Hagemeijer, Anne
    Schaefer, Hans-Eckart
    Baron, Frederic
    Ganser, Arnold
    Aul, Carlo
    de Witte, Theo
    Wijermans, Pierre W.
    Luebbert, Michael
    BLOOD, 2013, 122 (21)
  • [37] Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis
    Odenike, Olatoyosi M.
    Godwin, John E.
    Van Besien, Koen
    Huo, Dezheng
    Sher, Dorie
    Burke, Patrick
    Smith, Scott E.
    Green, Margaret
    Melnick, Julia
    Wade, James L.
    Lester, Eric P.
    Klisovic, Rebecca B.
    Baer, Maria R.
    Larson, Richard A.
    Stock, Wendy
    BLOOD, 2008, 112 (11) : 970 - 971
  • [38] Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Chien, Kelly S.
    Valero, Yesid Alvarado
    Daver, Naval
    Borthakur, Gautam
    Swaminathan, Mahesh
    Maiti, Abhishek
    Hammond, Danielle E.
    Nogueras-Gonzalez, Graciela
    Huang, Xuelin
    Schneider, Heather
    Shelly, Kristen
    Kadia, Tapan M.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2023, 142
  • [39] Cladribine, cytarabine and idarubicin (CAI) for remission induction in patients with relapsed AML - a phase II study
    Hahn-Ast, C.
    Glasmacher, A.
    Mayer, K.
    Schwab, K.
    Brossart, P.
    von Lilienfeld-Toal, M.
    ONKOLOGIE, 2012, 35 : 121 - 121
  • [40] Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study
    Li, Yanyan
    Zhou, Haixia
    Wan, Chaoling
    Xu, Mingzhu
    Qian, Chongsheng
    Zhang, Tongtong
    Dai, Haiping
    Sun, AiNing
    Wu, Depei
    Xue, Shengli
    BLOOD, 2022, 140 : 3212 - 3213
12345